Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Erbitux Fails First-Line Pancreatic Cancer Trial, But ImClone/Bristol Will Move Program Forward

This article was originally published in The Pink Sheet Daily

Executive Summary

Cetuximab is currently being evaluated in nine other Phase I and II trials for pancreatic cancer, which will continue.

You may also be interested in...



Erbitux Misses Primary Endpoint As First-Line Treatment In Phase III NSCLC Trial

Bristol-Myers Squibb/ImClone’s future for Erbitux in first-line NSCLC hinges on FLEX study findings, scheduled for release in first half of 2008.

Erbitux Misses Primary Endpoint As First-Line Treatment In Phase III NSCLC Trial

Bristol-Myers Squibb/ImClone’s future for Erbitux in first-line NSCLC hinges on FLEX study findings, scheduled for release in first half of 2008.

Erbitux Shows Survival Benefit With Chemo In First-Line Metastatic Head & Neck Cancer

ImClone/Bristol will discuss potential for submitting an sBLA for the indication with FDA.

Related Content

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel